Enfuvirtide

Overview

Enfuvirtide emerged from pioneering work by Carl Wild and Tom Matthews at Duke University in the early 1990s, who identified that synthetic peptides corresponding to the C-terminal heptad repeat (HR2) of HIV-1 gp41 could potently inhibit HIV-1 infection in vitro (Wild et al., 1994). The peptide exploits a critical vulnerability in the HIV entry mechanism: after the viral envelope glycoprotein gp120 binds CD4 and a co-receptor (CCR5 or CXCR4), gp41 undergoes a dramatic conformational rearrangement exposing its HR1 coiled-coil trimer. Enfuvirtide binds this transient HR1 intermediate, competitively blocking the interaction between HR1 and HR2 that would normally drive six-helix bundle formation and membrane fusion.

The development of enfuvirtide by Trimeris (later acquired by Roche) represented a proof-of-concept that viral entry could be therapeutically targeted with peptide drugs. Its clinical utility, however, has been constrained by the requirement for twice-daily subcutaneous injections, significant injection site reactions, high manufacturing cost, and the emergence of resistance mutations in the gp41 HR1 domain. Enfuvirtide is therefore reserved primarily for heavily treatment-experienced patients in salvage regimens where other active agents are limited.

Mechanism of Action

Enfuvirtide's mechanism targets the HIV-1 entry process at the membrane fusion step:

• HR1 binding: After gp120 engages CD4 and a co-receptor, gp41 extends its N-terminal fusion peptide toward the host cell membrane and exposes the HR1 coiled-coil trimer. Enfuvirtide binds this HR1 trimer in a dominant-negative fashion, mimicking the endogenous HR2 domain and preventing the native HR1-HR2 interaction (Chan et al., 1997).
• Six-helix bundle inhibition: The formation of the thermostable six-helix bundle (6-HB), in which three HR2 helices pack into the grooves of the HR1 trimer, is the energy source driving membrane fusion. By occupying the HR2-binding groove on HR1, enfuvirtide arrests this process at a pre-fusion intermediate state (Weissenhorn et al., 1997).
• Entry-stage specificity: Unlike reverse transcriptase or protease inhibitors, enfuvirtide acts extracellularly at the viral entry step, before the viral genome enters the host cell. This provides a mechanistically distinct target for combination therapy (Kilby et al., 1998).
• Strain specificity: Enfuvirtide is primarily active against HIV-1; it has limited activity against HIV-2 due to sequence divergence in the gp41 HR1 domain.

Reconstitution Calculator

Research

Safety Profile

Enfuvirtide's safety profile is well characterized from clinical trials and extensive post-marketing experience:

• Injection site reactions (ISRs): Occur in ~98% of patients; pain, induration, erythema, nodules, and pruritus at injection sites. ISRs are the most common reason for discontinuation. Rotating injection sites and proper technique reduce severity (Ball et al., 2003).
• Hypersensitivity: Rare (<1%) systemic hypersensitivity reactions including rash, fever, nausea, rigors, and hypotension; enfuvirtide should be discontinued and not rechallenge.
• Bacterial pneumonia: A higher rate of bacterial pneumonia was observed in enfuvirtide arms of TORO trials (4.68 vs 0.61 events per 100 patient-years); causal relationship uncertain.
• Eosinophilia: Observed in some patients; generally asymptomatic.
• Immune reconstitution: As with all effective antiretrovirals, immune reconstitution inflammatory syndrome (IRIS) may occur in patients with profound immunosuppression.

Pharmacokinetic Profile